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Abstract Membrane type 1 matrix metalloproteinase (MT1-
MMP) was suggested to play a critical role in the regulation of 
tissue invasion by normal and neoplastic cells by directly 
mediating the activation of pro-gelatinase A. Recently, the 
proteolytic activation of a pro-MTl-MMP by an intracellular 
proprotein convertase, furin, was reported. In this study, we 
found that plasmin efficiently activates the pro-MTl-MMP by 
cleaving immediately downstream of Arg1 and Arg111 in the 
multi-basic motif between its pro- and catalytic domains that 
participates in the activation of pro-gelatinase A. Our present 
data suggest that pro-MTl-MMP transported to the plasma 
membrane is activated by plasmin extracellularly and thus it may 
play an important role in the matrix degradation process. 
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1. Introduction 
Membrane type 1 matrix metalloproteinase (MT1-MMP) is 
believed to play a critical role in tumor cell invasion and 
degradation of the extracellular matrix by directly mediating 
the activation of pro-gelatinase A [1,2]. Like all other M M P s , 
M T - M M P is synthesized as an inactive precursor, and the 
zymogen is activated on proteolytic cleavage at a site in the 
multi-basic motif ( R R K / R R ) between its pro- and catalytic 
domains [3,4]. It was recently reported that furin, a proprotein 
convertase present in the Golgi apparatus, activates a trans-
membrane deletion mutan t of p r o - M T l - M M P [5] and GST-
p r o - M T l - M M P [6], resembling the action observed previously 
for stromelysin-3 [7]. In addition to the intracellular proteo-
lytic activation of p r o - M T l - M M P by furin, a number of lines 
of evidence suggest that M T 1 - M M P is transported to the 
plasma membrane in a latent precursor form. The M T 1 -
M M P expressed in transfected cells, human fibroblasts and 
HT-1080 human fibrosarcoma cells is a 63 k D a latent precur-
sor enzyme with a propeptide domain [1,8], or a partially 
processed 60 k D a latent protease [9], respectively. Based on 
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these data, we proposed a mechanism of p r o - M T l - M M P ac-
tivation on the cell surface, besides the intracellular mecha-
nism of activation mediated by furin, and searched for a po-
tential extracellular protease activator of p r o - M T l - M M P . 
Among extracellular trypsin-like proteases, only plasmin was 
found to activate p r o - M T l - M M P . N-Terminal amino acid 
sequence analyses of the products showed that plasmin has 
two processing sites, i.E. the R n l - Y 1 1 2 , and R108-R10!> bonds 
in the multi-basic cleavage motif of the propeptide. In gelatin 
zymography experiments, pro-gelatinase A was activated by 
plasmin-activated M T 1 - M M P , and this activation was inhib-
ited by the plasmin inhibitor, aprotinin, and the substrate 
analogue, dec-RVKR-cmk. Based on these results, it appears 
that p r o - M T l - M M P is activated not only by furin in the 
Golgi apparatus but also by plasmin on the cell surface. 
2. Materials and methods 
2.1. Materials 
Human plasmin was purchased from Boehringer Mannheim GmbH 
(Germany). Urokinase and protease inhibitors, aprotinin and al-anti-
trypsin, were from Sigma (Tokyo, Japan). Leupeptin, Boc-LKR-
MCA, Boc-RVRR-MCA and Pyr-RTKR-MCA were from the Pep-
tide Institute (Osaka, Japan). Inhibitors of furin, dec-RVKR-cmk and 
its derivative, dec-FAKR-cmk, were gifts from Dr. H.D. Klenk, Uni-
versity of Marburg. Tryptases from human lung were purified to 
homogeneity by the method described by Smith et al. [10]. Thrombin 
and factor Xa from bovine plasma were purified by the methods 
described by Hashimoto et al. [11]. A recombinant GST-pro-MTl-
MMP fusion protein containing the pro-, catalytic and hinge domains 
of MT1-MMP was obtained by the method described by Kinoshita et 
al. [12]. Pro-gelatinase A was obtained by the method described by 
Sato and Seiki [13]. 
2.2. Cleavage of the GST-pro-MTl-MMP fusion protein 
Cleavage of pro-MTl-MMP by various extracellular proteases was 
analyzed with the GST-pro-MTl-MMP fusion protein as a substrate 
without removing the GST domain, for elimination of protease con-
tamination of the assay system, and for elimination of denaturation of 
pro-MTl-MMP in the process of purification. The GST-pro-MTl-
MMP fusion protein (0.8 ug) was incubated with various proteases 
(2.7 pmol), and then incubated further for 15-60 min at 37°C in 20 ul 
of a reaction buffer (plasmin and urokinase, 0.1 M Tris-HCl buffer, 
pH 7.0; human lung tryptase, 0.1 M Tris-HCl buffer, pH 7.5, con-
taining 0.15 M NaCl and 2.5 ug/ml heparin; thrombin, 50 mM Tris-
HCl buffer, pH 7.8, containing 0.1 M NaCl and 20 mM EDTA; and 
factor Xa, 50 mM Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl 
and 10 mM C a C y . The reaction was terminated by cooling in ice and 
the addition of 3 X SDS-PAGE sample loading buffer [14], followed by 
analysis by SDS-PAGE under reducing conditions. 
2.3. Enzyme and inhibitor assays 
The amidolytic activities of proteases toward various synthetic pep-
tides were analyzed as follows: 25 ul of a test sample or diluted 
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sample was mixed with 2.5 ill (20 mM) of a substrate in 472.5 ill of 
the reaction buffer in a quartz cuvette controlled thermostatically at 
37°C. The reaction was started by the addition of the substrate, and 
then the amount of 7-amino-4-methylcoumarin liberated from the 
substrate was determined fluorimetrically, with excitation and emis-
sion wavelengths of 380 and 460 nm, respectively, using a Hitachi 
fluorescence spectrophotometer, 650-10MS model. One unit of en-
zyme activity was defined as the amount degrading 1 |xmol of sub-
strate per min. The Km values were determined from the hydrolysis 
rates at four separate substrate concentrations by Lineweaver-Burk 
plotting. To determine the effects of inhibitors, enzyme preparations 
were preincubated for 5 min with various inhibitors at 37°C and then 
the residual activity was measured. The inhibition constant (K¡) was 
determined from a Dixon plot. 
2.4. Electrophoresis and Western immunoblotting 
SDS-PAGE (10-20% gradient gel; Daiichi Pure Chemicals, Tokyo) 
was performed by the method of Laemmli [14] at room temperature. 
The gel was stained with silver. SDS-PAGE low range standards 
(APRO Science, Inc., Japan) were used as molecular weight markers 
(phosphorylase b (97.2 kDa), BSA (66.4 kDa), ovalbumin (45 kDa), 
carbonic anhydrase (29 kDa), soybean trypsin inhibitor (20.1 kDa), 
and lysozyme (14.3 kDa)). For Western blot analysis, the reaction 
samples were subjected to SDS-PAGE, and then transferred electro-
phoretically to an Immobilon transfer membrane (Millipore): excess 
sites were blocked with 3.5% skim milk in PBS. Each membrane was 
then probed with a mAb against MT1-MMP (114-2F2) [1] overnight 
at 4°C. The final concentration of the mAb was 1 u\g/ml in 3.5% skim 
milk in PBS. After extensive washing with TBS (20 mM Tris-HCl 
buffer, pH 7.5/0.5M NaCl), the membrane was reprobed with anti-
mouse IgG conjugated with horseradish peroxidase (Amersham, 
Amersham, UK), 1:1000, in 3.5% skim milk in PBS for 1 h at 
room temperature. The bound antibodies were detected with ECL 
Western blotting detection reagents (Amersham) according to the 
manufacturer's instructions. 
2.5. Amino acid sequences 
The N-terminal amino acid sequences of the proteolytic products 
were determined by the microsequencing method with an Applied 
Biosystems 492 model gas-phase sequencer/ 140C HPLC system after 
the reaction samples had been electrophoretically transferred to a 
ProBrot membrane (Applied Biosystems, Foster City, CA) according 
to the manufacturer's instructions. 
2.6. Activation of pro-gelatinase A and inhibition of its activation 
Pro-gelatinase A (0.7 |xg) was incubated with GST-pro-MTl-MMP 
(0.8 iig) and plasmin (2.7 pmol) in a reaction buffer (50 mM Tris-HCl 
buffer, pH 7.5/0.15 M NaCl/50 mM CaCl2/0.25 uM ZnCl2) in the 
presence or absence of a protease inhibitor (10 U.M), for 1 h at 
37°C, and then analyzed by gelatin zymography. 
2.7. Gelatin zymography 
Zymography was performed as described [15]. Samples were mixed 
with the SDS-PAGE sample buffer in the absence of a reducing agent 
and then incubated for 20 min at room temperature to denature the 
MMPs. Electrophoresis was performed on 12.5% polyacrylamide gels 
Fig. 1. A: Cleavage of GST-pro-MTl-MMP by various trypsin-type 
proteases. GST-pro-MTl-MMP (0.8 u,g) (lane 2) was incubated for 
60 min with various extracellular proteases (2.7 pmol), such as hu-
man lung tryptase (lane 3), thrombin (lane 4), factor Xa (lane 5), 
urokinase (lane 6), and plasmin (lane 7), and the reaction products 
were separated by SDS-PAGE. Molecular weight markers (lane 1). 
B: Time course of GST-pro-MTl-MMP cleavage by human plas-
min. GST-pro-MTl-MMP (0.8 u,g) was incubated with plasmin 
(2.7 pmol) for 0 (lane 2), 15 (lane 3), 30 (lane 4), and 60 min (lane 
5), followed by SDS-PAGE. Molecular weight markers (lane 1). C: 
Western immunoblotting analysis. The proteolytic products in B 
were also analyzed by Western immunoblotting with a mAb against 
the catalytic domain of MT-MMP-1. GST-pro-MT-MMP-1 (lane 2) 
was incubated with plasmin for 15 min (lane 3). GST as a control 
(lane 1). 
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containing 0.1% SDS and gelatin at a final concentration of 0.1% 
(w/v). Thereafter, the gels were washed in 2.5% Triton X-100 for 2 
h at room temperature to remove the SDS. The gels were then in-
cubated for 24 h at 37°C in a reaction buffer (50 mM Tris-HCl buffer, 
pH 7.6/0.15 M NaCl/10 mM CaCl2), and then stained with 0.1% 
Coomassie brilliant blue R-250. The location of gelatinolytic activity 
was detected as a clear band in the background of uniform staining. 
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Fig. 2. Identification of the plasmin cleavage sites in GST-pro-MTl-
MMP during activation. The N-terminal sequence of the 25.5 kDa 
fragment in Fig. 1 generated by plasmin was analyzed as described 
in Section 2, and is indicated by bold letters. The aligned amino 
acid sequence is the sequence of MT1-MMP deduced on cDNA se-
quencing [1,12]. The multi-basic cleavage motif of pro-MTl-MMP 
is underlined. 
3. Results and discussion 
3.1. Proteolytic activation of the GST-pro-MTl-MMP fusion 
protein 
We examined the effects of various extracellular trypsin-
type proteases on proteolytic activation of the GST-pro-
MTl-MMP fusion protein, which comprises GST, and the 
pro-, catalytic and hinge domains of MT1-MMP, and retains 
the latency of MT-MMP (Fig. 1A). Among the proteases 
tested, plasmin (lane 7) specifically converted the 58 kDa 
GST-pro-MTl-MMP fusion protein to a 25.5 kDa fragment, 
which roughly corresponds to the molecular mass of the cata-
lytic domain of MT1-MMP. On the other hand, thrombin 
cleaved GST-pro-MTl-MMP at the thrombin cleavage site 
at the junction between GST and the pro-domain of MT1-
MMP, producing a 26.5 kDa fragment (lane 4). The N-termi-
nal amino acid sequence of the 26.5 kDa fragment produced 
by thrombin supported this interpretation (data not shown). 
However, other extracellular or secretory proteases did not 
liberate a 25.5 kDa fragment, though some of them produced 
fragments with molecular masses higher than 27 kDa. Then, 
we examined the time-course of GST-pro-MTl-MMP cleav-
age by plasmin, the products being analyzed by SDS-PAGE 
(Fig. IB) and by Western immunoblotting with 114-1F2 mAb 
[1] against the catalytic domain of MT1-MMP (Fig. 1C). As 
was expected, the 58-kDa GST-pro-MTl-MMP band material 
was degraded in a time-dependent manner with the successive 
formation of 32, 28.5 and 25.5 kDa fragments. Degradation 
of the intermediate 32 kDa fragment was also observed on 
incubation for 15 min. Of these fragments, the 25.5 kDa one, 
but not the 32 and 28.5 kDa one, was stained with the mAb 
(Fig. 1C), suggesting that the 25.5 kDa fragment contains the 
catalytic domain of MT1-MMP. The N-terminal amino acid 
sequences of the 32, 28.5 and 26.5 kDa fragments revealed the 
N-terminal sequence of GST (data not shown), indicating that 
plasmin cleaved not only pro-MTl-MMP but also at sites in 
the GST domain. The contaminating protein with a molecular 
mass of about 26.5 kDa in the original sample of GST-pro-
MTl-MMP (Fig. 1A,B, lane 2; and C, lanes 2 and 3), which 
had the N-terminal sequence of GST and was slightly cross-
reactive with the mAb, was produced during the process of 
purification of the fusion protein by glutathione-sepharose 
affinity chromatography. The protein by itself, however, ex-
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hibited no ability of pro-gelatinase A activation, as suggest-
ed below in Fig. 3, lane 3. Taken together, the results indi-
cate that the 25.5 kDa fragment is the only major one of 
MT1-MMP, the others being N-terminal side fragments of 
GST. 
3.2. Cleavage site determination 
To determine the site of cleavage of GST-pro-MTl-MMP 
by plasmin, the N-terminal amino acid sequence of the 25.5 
kDa fragment was analyzed (Fig. 2). Sequence analysis of the 
25.5 kDa fragment revealed two sequences, Y(1.2)-A(1.2)-
I(2.2)-Q(1.7)-G(2.1)-L(1.4)-K(l.l)-W(1.0)-Q(1.3)-H(0.6), and 
R(1.4)-K(1.4)-R(1.2)-Y(1.3)-A(1.4)-I(2.5)-Q(1.8)-G(2.0)-
L(l.l)-K(1.2) (the values in parentheses are the yields in 
pmol). This indicates that the R108-R109 and R l u -Y 1 1 2 bonds 
of the multi-basic cleavage motif between the pro- and cat-
alytic domains of MT1-MMP are cleaved with almost the 
same efficiency during the activation by plasmin. In the 
case of furin, the R m - Y n 2 bond is specifically processed 
[5,6], and the same site of cleavage by pancreatic trypsin of 
the proform of the catalytic domain of MT1-MMP was pre-
viously reported [2]. Analysis of the substrate specificity of 
plasmin revealed that it exhibits similar Km values for a syn-
thetic plasmin substrate (Boc-LKR-MCA) (Äm = 4 . 2 x l 0
- 4 
M) and a synthetic furin substrate (Boc-RVRR-MCA) 
(A:m = 4 .8xl0~
4 M). Taken together, these results suggest 
that the consensus cleavage motif, RXK/RR, of pro-MTl-, 
2-, 3- and 4-MMP, and stromelysin-3 zymogen is recognized 
by plasmin as well as furin. 
3.3. Activation of pro-gelatinase A by plasmin-activated 
MT1-MMP and its inhibition by plasmin inhibitors 
In order to confirm the proteolytic activity of MT1-MMP 
produced from the zymogen by plasmin, we analyzed the ac-
tivation of pro-gelatinase A. Current evidence indicates that 
MT1-MMP initiates 68-kDa pro-gelatinase A activation via a 
two-step process comprising initial cleavage of the N37-L38 
bond, followed by autocatalytic conversion of the 64 kDa 
L38 intermediate to a 62 kDa active enzyme with an N-termi-
nal Y81 residue [16,17]. As shown in Fig. 3, neither plasmin 
(lane 2) nor thrombin (lane 3) activated pro-gelatinase A di-
rectly, and only pro-MTl-MMP incubated with plasmin (lane 
Fig. 3. Cleavage of pro-gelatinase A by plasmin-activated pro-MTl-
MMP. Gelatin zymography of pro-gelatinase A (0.7 ug) (lane 1), 
pro-gelatinase A treated with various proteases (2.7 pmol), such as 
plasmin (lane 2) and thrombin (lane 3), GST-pro-MTl-MMP 
(0.8 ug) (lane 4), GST-pro-MTl-MMP treated with plasmin (lane 5), 
and GST-pro-MTl-MMP treated with thrombin (lane 6) was per-
formed. The experimental conditions for gelatin zymography are 
given in Section 2. 
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activation of p ro -MT-MMPs by plasmin may be of specific 
advantage to malignant cells. 
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